| Similar Articles |
|---|
 |
Chemistry World
February 4, 2014
Phillip Broadwith |
Merck & Co doubles up on Ablynx research deal This collaboration will focus on nanobodies (antibody fragments) directed against cancer.   |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
Chemistry World
March 10, 2015
Anmdrew Turley |
AbbVie to buy Pharmacyclics for pipeline boost AbbVie has agreed to buy US biotech Pharmacyclics for $21 billion in a bid to re-stock its pipeline. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
Chemistry World
October 2, 2012
Andrew Turley |
Merck & Co $460m ion channel deal Merck & Co has struck a $460 million deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. |
American Family Physician
December 1, 2003
Gill et al. |
Diagnosis of Systemic Lupus Erythematosus Systemic lupus erythematosus is a multisystem inflammatory disease that is often difficult to diagnose. Before the diagnosis can be established, four of 11 clinical and laboratory criteria must be met. |
American Family Physician
March 15, 2002
Stephen K. Lane & Joseph W. Gravel, Jr. |
Clinical Utility of Common Serum Rheumatologic Tests Many serum rheumatologic tests have been available for fewer than 10 years. As a result, some physicians are not fully aware of the indications, sensitivity, specificity, cost and clinical utility of these tests... |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion. |
